Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer. (Q54331057)
Jump to navigation
Jump to search
scientific article published on 14 August 2014
Language | Label | Description | Also known as |
---|---|---|---|
English | Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer. |
scientific article published on 14 August 2014 |
Statements
Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer (English)
J Salvador
L Manso
J de la Haba
A Jaen
M C de Villena
M Gil
A Murias
A Galan
C Jara
J Bayo
J M Baena
J Casal
J R Mel
I Blancas
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference